BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16906584)

  • 41. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
    Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S
    Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
    Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
    Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
    Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
    Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
    Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.
    Hojjat Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Shamsian Khoramabadi A; Rabbani H; Shokri F
    Iran J Immunol; 2008 Mar; 5(1):25-35. PubMed ID: 18319522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
    Chen YH; Peterson LC; Dittmann D; Evens A; Rosen S; Khoong A; Shankey TV; Forman M; Gupta R; Goolsby CL
    Am J Clin Pathol; 2007 Feb; 127(2):182-91. PubMed ID: 17210531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J; Babusíková O
    Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients.
    Monserrat J; Sánchez MÁ; de Paz R; Díaz D; Mur S; Reyes E; Prieto A; de la Hera A; Martínez-A C; Alvarez-Mon M
    Cytometry B Clin Cytom; 2014 Jan; 86(1):32-43. PubMed ID: 24166938
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels.
    Rivkina A; Vitols G; Murovska M; Lejniece S
    Exp Oncol; 2011 Jun; 33(2):99-103. PubMed ID: 21716207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
    Carreras J; Villamor N; Colomo L; Moreno C; Ramón y Cajal S; Crespo M; Tort F; Bosch F; López-Guillermo A; Colomer D; Montserrat E; Campo E
    J Pathol; 2005 Mar; 205(4):507-13. PubMed ID: 15685592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
    Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
    Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of ZAP-70 in patients with chronic lymphocytic leukemia.
    Marjanovic G; Stanojevic I; Jankovic-Velickovic Lj; Hubl W; Marjanovic V
    J BUON; 2008; 13(4):543-6. PubMed ID: 19145677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection].
    Smolej L; Saudková L; Spacek M; Kozák T
    Vnitr Lek; 2006 Dec; 52(12):1194-9. PubMed ID: 17299914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL).
    Capello D; Zucchetto A; Degan M; Bomben R; Dal Bo M; Efremov DG; Laurenti L; Del Poeta G; Gaidano G; Gattei V
    Leuk Res; 2006 Sep; 30(9):1197-9. PubMed ID: 16417919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
    Zucchetto A; Bomben R; Dal Bo M; Sonego P; Nanni P; Rupolo M; Bulian P; Dal Maso L; Del Poeta G; Del Principe MI; Degan M; Gattei V
    J Cell Physiol; 2006 May; 207(2):354-63. PubMed ID: 16331666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Soma LA; Craig FE; Swerdlow SH
    Hum Pathol; 2006 Feb; 37(2):152-9. PubMed ID: 16426914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.